23:32 , Sep 14, 2018 |  BC Extra  |  Preclinical News

UCSD researchers identify mechanism, target in NASH

Researchers from the University of California San Diego have identified a key mechanism behind the pathogenesis of non-alcoholic steatohepatitis (NASH), which could lead to a therapeutic approach and biomarkers of disease progression. Caspases are suspected...
08:00 , Nov 9, 2015 |  BC Week In Review  |  Clinical News

QPI-1007: Phase II/III started

SBI Biotech’s Quark Pharmaceuticals Inc. subsidiary began a double-blind, sham-controlled, international Phase II/III trial to evaluate 1.5 and 3 mg QPI-1007 per eye given as a single intravitreal injection or as 3 injections 2 months...
07:00 , Jul 24, 2014 |  BC Innovations  |  Cover Story

It is an RNA world

RNA-based molecules have redefined the universe of tractable targets by putting virtually anything that is gene encoded within reach of a disease-modifying agent. This redefinition has launched RNA as the biotech industry's third drug modality....
07:00 , Jul 21, 2014 |  BC Week In Review  |  Clinical News

QPI-1007: Phase IIa started

SBI Biotech’s Quark Pharmaceuticals Inc. subsidiary began a double-blind, sham-controlled, international Phase IIa trial to evaluate single intravitreal injections of 1.5 mg QPI-1007 in about 60 patients with unilateral acute primary angle-closure glaucoma. RiboQuark -...
01:30 , Jan 8, 2014 |  BC Extra  |  Financial News

RiboQuark raises $7.4 million in A round

Kunshan RiboQuark Pharmaceutical Technology Co. Ltd. (Kunshan, China) raised almost RMB45 million ($7.4 million) in a series A round led by BVCF. SBI Incubation; Kunshan Industrial Technology Research Institute Investment; and Kunshan Hongtu Hi-tech Venture...
08:00 , Dec 23, 2013 |  BC Week In Review  |  Company News

Biocon, SBI Holdings deal

Biocon partnered with Quark Pharmaceuticals Inc. to co-develop therapeutics using Quark's short interfering RNA technology. Under the deal, Biocon gains rights to co-develop and commercialize Quark's QPI-1007 in India and other undisclosed markets. QPI-1007, an...
02:02 , Dec 19, 2013 |  BC Extra  |  Company News

Biocon up on siRNA deal

Biocon Ltd. (NSE:BIOCON; BSE:BIOCON) partnered with Quark Pharmaceuticals Inc. to co-develop therapeutics using Quark's short interfering RNA technology. Under the deal, Biocon gains rights to co-develop and commercialize Quark's QPI-1007 in India and other undisclosed...
08:00 , Jan 16, 2012 |  BC Week In Review  |  Clinical News

QPI-1007: Phase I data

Interim data from an open-label, dose-escalation, international Phase I trial in 38 patients showed a single injection of QPI-1007 had no dose limiting toxicities up to and including the highest dose of 6 mg. The...
07:00 , Oct 4, 2010 |  BioCentury  |  Finance

Tel Aviv transit

Tel Aviv transit Functional genomics play Quark Pharmaceuticals Inc. is headed to Tel Aviv to launch its IPO while BioLineRx Ltd. (Tel Aviv:BLRX) is going the other way to add a NASDAQ listing. Quark filed...
00:03 , Sep 28, 2010 |  BC Extra  |  Financial News

Quark seeking IPO in Tel Aviv

Quark Pharmaceuticals Inc. (Fremont, Calif.) filed to raise up to $20 million through the sale of units in an IPO on the Tel Aviv Stock Exchange. The offering is not underwritten. Quark has two compounds...